AstraZeneca scrapped a £450m vaccine plant in Liverpool after the UK government missed a critical funding deadline. The pharma giant warns Britain is becoming one of the hardest places to attract ...
Clinical Trials Arena on MSN21h
AstraZeneca’s $1bn hypoparathyroidism drug achieves success at Phase IIIUK-based AstraZeneca’s acquired rare disease drug has met the primary endpoint in a Phase III trial in patients with chronic ...
Monday was a busy day for AstraZeneca, which also paid up to $1 billion to acquire Belgian biotech EsoBiotec and its cell therapy pipeline and technology.
AstraZeneca's eneboparatide met its Phase 3 trial goal for chronic hypoparathyroidism, while the EU approved Imfinzi for ...
UBS analyst Matthew Weston maintained a Buy rating on AstraZeneca (AZN – Research Report) today and set a price target of £142.00. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback